Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 611-618

  Abubaker, Jehad ^a   Jehan, Zeenath ^a   Bavi, Prashant ^a   Sultana, Mehar ^a   Al Harbi, Sayer ^a   Ibrahim, Muna ^a   Al Nuaim, Abdulrahman ^a   Ahmed, Mohammed ^a   Amin, Tarek ^a   Al Fehaily, Maha ^a   Al Sanea, Osama ^b   Al Dayel, Fouad ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE EAST; ONCOGENE RAS; PIK3CA GENE; POPULATION GENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THYROID CANCER;

EID: 39049169179     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1717     Document Type: Article

References (31)

1. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumornode-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562
2. Hay ID 1990 Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576
3. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, Haglund C 2005 Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57-64
4. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
5. Wang Y, Hou P, Yu H, Wang W, Ji M, Hao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M 2007 High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors. J Clin Endocrinol Metab 92:2387-2390
6. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693
7. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170
8. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J 1994 Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532
9. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
10. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M 1999 Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-822
11. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752
12. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Alnuaim A, Alzahrani A, Ahmed M, Alsanea O, Uddin S, Al-Kuraya K 2007 Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213:190-199
13. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, Amr SS, Sheikh SS, Ezzat A, El-Solh H, Uddin S, Al-Kuraya K 2006 Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 15:1708-1718
14. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R 2006 Estrogen receptor α (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655-660
15. Wagner U, Bubendorf L, Gasser TC, Moch H, Goαroαg JP, Richter J, Mihatsch MJ, Waldman FM, Sauter G 1997 Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 151:753-759
16. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE 2005 Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561-573
17. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559
18. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S, Al-Kuraya K 2007 PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21:2368-2370
19. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
20. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS 2006 Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178-4186
21. Pfaffl MW, Horgan GW, Dempfle L 2002 Relative expression software tool [REST(C)] for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
23. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
24. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397
25. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567
26. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
27. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457
28. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are-associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7740
29. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S 2004 Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4280-4284
30. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M 2004 BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4267-4271
31. Espinosa AV, Porchia L, Ringel MD 2007 Targeting BRAF in thyroid cancer. Br J Cancer 96:16-20